Understanding Non-Hodgkin Lymphoma

Dear Stacey: Are There Costly Consequences to Co-Pay Accumulator Programs?

What is a co-pay accumulator, and how will it affect cancer patients access to treatment? Noted healthcare attorney Stacey Worthy discusses what patients need to know about the “double-dip” insurance deductible.

Published:

Follicular Lymphoma Updates From ASH 2018

Dr. Neel Gupta speaks with Andrew Schorr about new and improving therapies for follicular lymphoma from ASH 2018.

Published:

Follicular Lymphoma News at ASH 2018: An Update From Dr. Peter Martin

From the 2018 American Society of Hematology (ASH) annual meeting in San Diego, Patient Power founder Andrew Schorr is joined by leading expert Dr. Peter Martin to discuss follicular lymphoma treatment news announced at the conference. Watch now to stay up-to-date with the latest research.

Published:

Peripheral T-Cell Lymphoma Updates From ASH 2018 With Dr. Gupta

Lee Swanson is joined by Dr. Neel K. Gupta of Stanford University School of Medicine. They discuss changes since last year’s ASH meeting.

Published:

Updates From ASH 2018 Peripheral T-Cell Lymphoma With Dr. Horwitz

Dr. Steven Horwitz joins Lee Swanson to discuss new approvals and advancements made in peripheral T-cell lymphoma at ASH 2018. Dr. Steven Horwitz has been instrumental in these studies leading to approval for new treatments.

Published:

ASH 2018 Daily Wrap: MPN News

On location in San Diego, Patient Power founders Andrew and Esther Schorr are joined by a panel of experts to discuss research developments announced at ASH 2018. Watch day one of Patient Power’s daily wrap to hear the latest blood cancer-related treatment news.

Published:

Clinical Trial MythBusters: What Is the Value of Diversity in Clinical Trials?

Is diversity, gender, age and ethnicity important in clinical trials? Mel Mann, a 20+ year CML survivor and a a highly respected leader in the field of clinical oncology weigh in.

Published:

Will I Feel Like a Guinea Pig? A Four-Time Clinical Trial Participant Shares Her Experience

A common question patients have when considering a clinical trial is “will I be a guinea pig?” Meet Reina Weiner, a four-time clinical trial participant, as she shares her experience navigating the trial process, patient consent, safety, risks, family issues and more.

Published:

Can Low Clinical Trial Participation Inhibit Cancer Research and Innovation?

Lazarex chairman Dana Dornsife says that there’s a “48 percent failure rate of clinical trials, and it's not because the drug didn't work.” Why do some medicines never make it to market? Watch now to find out.

Published:

Showing 9 of 96 programs
Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on April 27, 2018